Mary-Ellen Taplin
Professor of Medicine at Harvard Medical School
Biography
Harvard Medical School
Dr. Taplin received her MD in 1986 from the University of Massachusetts, Worcester. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center and an oncology-hematology fellowship at Beth Israel Hospital and Harvard Medical School. Dr. Taplin was on staff in medical oncology-hematology as an assistant and then associate professor of medicine at the University of Massachusetts from 1993 to 2003, when she joined Dana-Farber Cancer Institute.
Clinical Interests
- Bladder cancer
- Clinical trials
- Hormone and chemotherapy
- Kidney cancer
- Prostate cancer
- Testis cancer
Videos
Biologic rationale for next-generation AR inhibitors - Mary-Ellen Taplin
Dana-Farber Cancer Institute: Mary-Ellen Taplin, MD (ASCO GU21 prostate cancer)
Helping patients make the best choice for them: Dr. Mary-Ellen Taplin | Dana-Farber Cancer Institute
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
Dr. Mary-Ellen Taplin on Treating Prostate/GU Cancers | Dana-Farber Cancer Institute
Dr. Mary-Ellen Taplin on Dual Pathway Inhibition in Prostate Cancer
Dr. Taplin on ARMOR3-SV Trial for Patients with mCRPC
Key considerations for the VISION trial of LuPSMA in mCRPC | Mary-Ellen Taplin
Dr. Mary-Ellen Taplin on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate
Dr. Mary-Ellen Taplin on Abiraterone Acetate's Mechanism of Action
Dr. Mary-Ellen Taplin on the Mechanism of Action of Enzalutamide (MDV3100)
Read about executive education
Other experts
Popular Courses
Looking for an expert?
Contact us and we'll find the best option for you.